| 1 |
Brown S, Banfill K, Aznar MC, et al. The evolving role of radiotherapy in non-small cell lung cancer[J]. Br J Radiol, 2019, 92(1104): 201-204.
|
| 2 |
Burdett S, Rydzewska L, Tierney J, et al. Postoperative radiotherapy for non-small cell lung cancer[J]. Cochrane Database Syst Rev, 2016, 10(10): D2142.
|
| 3 |
Brooks ED, Verma V, Senan S, et al. Salvage therapy for locoregional recurrence after stereotactic ablative radiotherapy for early-stage NSCLC[J]. J Thorac Oncol, 2020, 15(2): 176-189.
|
| 4 |
Ko EC, Raben D, Formenti SC. The integration of radiotherapy with immunotherapy for the treatment of non-small cell lung cancer[J]. Clin Cancer Res, 2018, 24(23): 5792-5806.
|
| 5 |
Iyengar P, Wardak Z, Gerber DE, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: A phase 2 randomized clinical trial[J]. JAMA Oncol, 2018, 4(1): e173-e175.
|
| 6 |
Gelatti A, Drilon A, Santini FC. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)[J]. Lung Cancer, 2019, 137(4): 113-122.
|
| 7 |
Wu SG, Shih JY. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer[J]. Mol Cancer, 2018, 17(1): 38-39.
|
| 8 |
Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer[J]. N Engl J Med, 2018, 378(2): 113-125.
|
| 9 |
Cheng H, Li XJ, Wang XJ, et al. A meta-analysis of adjuvant EGFR-TKIs for patients with resected non-small cell lung cancer[J]. Lung Cancer, 2019, 137(6): 7-13.
|
| 10 |
Jiang T, Zhang Y, Li X, et al. EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases[J]. Eur J Cancer, 2019, 121(1): 98-108.
|
| 11 |
Ballard P, Yates JW, Yang Z, et al. Preclinical Comparison of osimertinib with other EGFR-TKIs in EGFR-Mutant NSCLC Brain metastases models, and early evidence of clinical brain metastases activity[J]. Clin Cancer Res, 2016, 22(20): 5130-5140.
|
| 12 |
中华医学会，中华医学会肿瘤学分会，中华医学会杂志社. 中华医学会肺癌临床诊疗指南(2019版)[J]. 中华肿瘤杂志，2020, 42(4): 257-287.
|
| 13 |
邓小茜，戈 伟. SBRT与IMRT治疗早期非小细胞肺癌的疗效与生存情况分析[J]. 武汉大学学报(医学版), 2020, 41(5): 754-757.
|
| 14 |
Boyd MR, Paull KD. Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen[J]. Drug Dev Res, 2010, 34(2): 91-109.
|
| 15 |
陈宏达，郑荣寿，王 乐，等. 2019年中国肿瘤流行病学研究进展[J]. 中华疾病控制杂志，2020, 24(4): 373-379.
|
| 16 |
Takeda M, Nakagawa K. First- and second-generation EGFR-TKIs are all replaced to osimertinib in chemo-naive EGFR mutation-positive non-small cell lung cancer？[J]. Int J Mol Sci, 2019, 20(1): 402-403.
|
| 17 |
Hsu PC, Jablons DM, Yang CT, et al. Epidermal growth factor receptor (EGFR) pathway, yes-associated protein (YAP) and the regulation of programmed death-ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC)[J]. Int J Mol Sci, 2019, 20(15): 214-216.
|
| 18 |
Yoneda K, Imanishi N, Ichiki Y, et al. Treatment of non-small cell lung cancer with EGFR-mutations[J]. J UOEH, 2019, 41(2): 153-163.
|
| 19 |
Russo A, Franchina T, Ricciardi G, et al. Heterogeneous responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with uncommon EGFR mutations: new insights and future perspectives in this complex clinical scenario[J]. Int J Mol Sci, 2019, 20(6): 175-177.
|
| 20 |
Recondo G, Facchinetti F, Olaussen KA, et al. Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI？[J]. Nat Rev Clin Oncol, 2018, 15(11): 694-708.
|
| 21 |
Castellanos E, Feld E, Horn L. Driven by mutations: The predictive value of mutation subtype in EGFR-mutated non-small cell lung cancer[J]. J Thorac Oncol, 2017, 12(4): 612-623.
|
| 22 |
杨 玖，洪 梅，刘志远，等. 放疗联合EGFR-TKI靶向治疗对Ⅳ期非小细胞肺癌患者血清肿瘤标记物及疗效的影响[J]. 河北医学，2020, 26(1): 4-8.
|
| 23 |
Saida Y, Watanabe S, Abe T, et al. Efficacy of EGFR-TKIs with or without upfront brain radiotherapy for EGFR-mutant NSCLC patients with central nervous system metastases[J]. Thorac Cancer, 2019, 10(11): 2106-2116.
|
| 24 |
Tan CS, Kumarakulasinghe NB, Huang YQ, et al. Third generation EGFR TKIs: current data and future directions[J]. Mol Cancer, 2018, 17(1): 29-30.
|
| 25 |
Shetty V, Babu S. Management of CNS metastases in patients with EGFR mutation-positive NSCLC[J]. Indian J Cancer, 2019, 56(9): S31-S37.
|
| 26 |
Baraibar I, Mezquita L, Gil-Bazo I, et al. Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC[J]. Crit Rev Oncol Hematol, 2020, 148(3): 102-104.
|
| 27 |
Lin A, Wei T, Meng H, et al. Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations[J]. Mol Cancer, 2019, 18(1): 139-141.
|
| 28 |
吴海波，刘若男，高 敏，等. 非小细胞肺癌患者血清肿瘤异常蛋白的表达与化疗疗效的相关性[J]. 临床肺科杂志，2020, 25(9): 1395-1399.
|
| 29 |
Rebuzzi SE, Alfieri R, La Monica S, et al. Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: Review of the literature and future perspectives [J]. Crit Rev Oncol Hematol, 2020, 146(9): 102-104.
|
| 30 |
聂志凤. EGFR-TKI单药或联合放疗治疗非小细胞肺癌肺毒性研究进展[J]. 中国肿瘤临床，2017, 44(11): 558-561.
|